Introduction, Disclosures

Major findings from ESMO 2023, including clinical trial data  relevant to both community and health-system practice and recognized barriers to implementing those findings in practice. • Neoadjuvant therapy • Brain metastasis • Biomarkers • Immuno-oncology • Adjuvant therapy • Targeted therapy

Clinical practice and patient cases

Concluding remarks

By the end of the session the participant will be able to:

• Recall the optimal approach(es) to grading pathologic response to neoadjuvant therapy in melanoma and whether non-responders may benefit from adjuvant targeted or immunotherapy, and apply that information to a patient case.
• Describe the role of targeted and immunotherapy in patients with melanoma and brain metastasis.
• Identify which patients with melanoma would benefit from combination immune checkpoint inhibitor therapy.
• Discuss whether adjuvant therapy should be used in patients with melanoma, and apply that information to a patient case.

ACCME Activity #202584376

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Adil Daud, MD, Professor of Clinical Medicine, UCSF School of Medicine, has received financial compensation from research grant and/or consulting work from Merck, Bristol-Myers Squibb, Pfizer, Regeneron.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version